SCHEMBL7665294

SCHEMBL7665294

COc1ccc(C2NC(=O)c3ccccc3N2)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 1.00
KDM4E B2RXH2 5/20 1.00
MAPT P10636 3/20 1.00
HPGD P15428 2/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
TNKS2 Q9H2K2 6/20 0.68
GAA P10253 4/20 0.57
TNKS O95271 2/20 0.57
PARP3 Q9Y6F1 2/20 0.57
KMT2A Q03164 3/20 0.56
HSD17B10 Q99714 2/20 0.56
MEN1 O00255 2/20 0.56
RAB9A P51151 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
MAPK1 P28482 1/20 0.56
LMNA P02545 1/20 0.54
TSHR P16473 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30257239 1.00 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL28992939 0.88 KDM4E (0.78) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL13643405 0.88 KDM4E (0.78) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL30230074 0.87 ALDH1A1 (0.76) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL30230208 0.87 ALDH1A1 (0.76) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL28992909 0.87 ALDH1A1 (0.76) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL13643404 0.87 ALDH1A1 (0.76) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL28992949 0.87 ALDH1A1 (0.76) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL30230250 0.85 KDM4E (0.72) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL28992940 0.85 KDM4E (0.72) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115433134-B Catalytic enantioselective synthesis method of dihydroquinazolinone 哈尔滨工业大学(深圳) 2024-05-28 CN disclosed
CN-115433134-A Catalytic enantioselective synthesis method of dihydro quinazolinone 哈尔滨工业大学(深圳) 2022-12-06 CN disclosed
US-8883809-B2 Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-11-11 US disclosed
US-20120283439-A1 ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Redearch (IN) 2012-11-08 US disclosed
US-6479499-B1 INHIBITORS OF TUBULIN POLYMERIZATION NATIONAL SCIENCE COUNCIL (TW) 2002-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283439-A1 ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF NDUFAF1, TOP1, COX4I1 ALDH1A1 212/4885KDM4E 2437/4885MAPT 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.